Real life use of natalizumab, fingolimod, dimethylfumarate, teriflunomide and alemtuzumab in Austria: benefit-risk data from the Austrian Multiple Sclerosis Treatment Registry

被引：0
|
作者：
Guger, M. [1 ]
Enzinger, C. [2 ]
Leutmezer, F. [3 ]
Kraus, J. [4 ]
Berger, T. [5 ]
机构：
[1] Kepler Univ Clin, Clin Neurol 2, Med Campus 3, Linz, Austria
[2] Med Univ Graz, Dept Neurol, Graz, Austria
[3] Med Univ Vienna, Dept Neurol, Vienna, Austria
[4] Publ Hosp Zell Am See, Dept Neurol, Zell Am See, Austria
[5] Med Univ Innsbruck, Dept Clin Neurol, Innsbruck, Austria
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1510
引用
收藏
页码：788 / 789
页数：2
相关论文
共 50 条
  • [41] The effect of alemtuzumab treatment in relapsing remitting multiple sclerosis: real-world data from a five-year prospective one center study
    Sandgren, S.
    Novakova, L.
    Axelsson, M.
    Malmestrom, C.
    Zetterberg, H.
    Lycke, J.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 615 - 615
  • [42] The effect of alemtuzumab treatment on neurodegeneration in relapsing remitting multiple sclerosis: real-world data from a five-year prospective one center study
    Sandgren, S.
    Novakova, L.
    Axelsson, M.
    Malmestrom, C.
    Zetterberg, H.
    Lycke, J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 248 - 249
  • [43] Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry
    Braune, Stefan
    Rossnagel, Fabian
    Dikow, Heidi
    Bergmann, Arnfin
    BMJ OPEN, 2021, 11 (08):
  • [44] Burden of treatment and quality of life in relapsing remitting multiple sclerosis patients under early high efficacy therapy in argentina: data from the argentinean registry
    Ignacio Rojas, Juan
    Carnero Contentti, Edgar
    Alonso, Ricardo
    Tavolini, Dario
    Burgos, Marcos
    Federico, Belen
    Patrucco, Liliana
    Cristiano, Edgardo
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 763 - 764
  • [45] Burden of treatment and quality of life in relapsing remitting multiple sclerosis patients under early high efficacy therapy in Argentina: Data from the Argentinean registry
    Rojas, Juan I.
    Contentti, Edgar Carnero
    Alonso, Ricardo
    Tavolini, Dario
    Burgos, Marcos
    Federico, Belen
    Patrucco, Liliana
    Cristiano, Edgardo
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 85
  • [46] Changes in paediatric-onset multiple sclerosis treatment strategy over time: real world data from the Swiss Paediatric Inflammatory Brain Disease Registry
    Hulliger, Lorena
    Christen, Isabella
    Dill, Patricia
    Garcia-Tarodo, Stephanie
    Susanne, Hofer
    Kalser, Judith
    Maier, Oliver
    Oesch, Gabriela
    Bigi, Sandra
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 664 - 665
  • [47] No evidence of disease activity status among patients with relapsing-remitting multiple sclerosis on long-term natalizumab treatment: data from a real-world cohort in the Czech Republic
    Horakova, D.
    Vaneckova, M.
    Krasensky, J.
    Seidl, Z.
    van Pesch, V.
    van Wijmeersch, B.
    Ribbens, A.
    van Hecke, W.
    Freudensprung, U.
    Hyde, R.
    Ho, P. -R.
    Kokic, M.
    Uher, T.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 409 - 410
  • [48] Obese hypogonadal men with a history of cardiovascular diseases (CVD) benefit from long-term treatment with testosterone undecanoate (TU): observational, real-life data from a registry study
    Saad, F.
    Haider, A.
    Haider, K. S.
    Doros, G.
    Traish, A.
    EUROPEAN HEART JOURNAL, 2015, 36 : 474 - 474
  • [49] A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis
    Spelman, Timothy
    Havrdova, Eva
    Horakova, Dana
    Trojano, Maria
    Lugaresi, Alessandra
    Izquierdo, Guillermo
    Grammond, Pierre
    Duquette, Pierre
    Alroughani, Raed
    Pucci, Eugenio
    Granella, Franco
    Lechner-Scott, Jeannette
    Sola, Patrizia
    Ferraro, Diana
    Grand'Maison, Francois
    Terzi, Murat
    Rozsa, Csilla
    Boz, Cavit
    Hupperts, Raymond
    Van Pesch, Vincent
    Oreja-Guevara, Celia
    Jokubaitis, Vilija
    Kalincik, Tomas
    Butzkueven, Helmut
    NEUROLOGY, 2018, 90
  • [50] Risk of Becoming Wheelchair-Confined in Patients with Primary Progressive Multiple Sclerosis: Data from the ORATORIO Trial and a Long-Term Real-World Cohort from MSBase Registry
    Butzkueven, H.
    Spelman, T.
    Horakova, D.
    Slee, M.
    Hughes, S.
    Solaro, C.
    Izquierdo, G.
    Sola, P.
    Ferraro, D.
    Giovannoni, G.
    Havrdova, E. Kubala
    Kappos, L.
    Hauser, S. L.
    Montalban, X.
    Wormser, D.
    Model, F.
    Wang, Q.
    Freitas, R.
    Belachew, S.
    Wolinksy, J. S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 320 - 321
12345